(0.06%) 5 103.16 points
(0.15%) 38 299 points
(0.09%) 15 942 points
(-1.44%) $82.64
(5.77%) $2.03
(0.29%) $2 353.90
(-0.24%) $27.47
(3.87%) $957.80
(-0.18%) $0.933
(-0.32%) $10.99
(-0.50%) $0.796
(1.70%) $93.44
4 days till quarter result
(bmo 2024-05-03)
Expected move: +/- 9.69%
1.89% $ 20.48
@ $25.17
Ausgestellt: 14 Feb 2024 @ 15:30
Rendite: -18.63%
Vorheriges Signal: Feb 13 - 15:31
Vorheriges Signal:
Rendite: -0.59 %
Live Chart Being Loaded With Signals
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally...
Stats | |
---|---|
Tagesvolumen | 102 941 |
Durchschnittsvolumen | 215 987 |
Marktkapitalisierung | 609.99M |
EPS | $0 ( 2024-02-28 ) |
Nächstes Ertragsdatum | ( $-0.330 ) 2024-05-03 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.64 |
ATR14 | $0.0210 (0.10%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Hsieh Ming | Buy | 1 000 000 | Forward sale contract (obligation to sell) |
2024-03-08 | Hsieh Ming | Sell | 1 000 000 | Forward sale contract (obligation to sell) |
2024-03-01 | Xie Jian | Sell | 1 075 | Common Stock |
2024-03-01 | Xie Jian | Sell | 404 | Common Stock |
2024-03-01 | Kim Paul | Sell | 1 129 | Common Stock |
INSIDER POWER |
---|
2.45 |
Last 99 transactions |
Buy: 2 068 563 | Sell: 1 956 842 |
Volumen Korrelation
Fulgent Genetics Inc Korrelation
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Fulgent Genetics Inc Korrelation - Währung/Rohstoff
Fulgent Genetics Inc Finanzdaten
Annual | 2023 |
Umsatz: | $289.21M |
Bruttogewinn: | $96.61M (33.40 %) |
EPS: | $-5.63 |
FY | 2023 |
Umsatz: | $289.21M |
Bruttogewinn: | $96.61M (33.40 %) |
EPS: | $-5.63 |
FY | 2022 |
Umsatz: | $618.97M |
Bruttogewinn: | $366.90M (59.28 %) |
EPS: | $4.76 |
FY | 2021 |
Umsatz: | $992.58M |
Bruttogewinn: | $777.05M (78.29 %) |
EPS: | $17.25 |
Financial Reports:
No articles found.
Fulgent Genetics Inc
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.